Glucagon-Like Peptide 1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus. Edited by David M Nathan and Katya Rubinow, UpToDate, Wolters Kluwer, 9 Nov
The glucagon arm distinguishes it from tirzepatide (GIP/GLP-1 dual) and semaglutide (GLP-1 mono), and is the mechanistic basis for the hepatic fat-oxidation signal, including the reported 86% liver-fat reduction cited in 2026 secondary summaries [1][2] [unverified]
Caroline Messer, an endocrinologist at Northwell Lenox Hill Hospital, told The Post, of working with patients to get to the root cause of their obesity or weight gain
The exact cause of rosacea, a skin condition that causes redness and visible blood vessels in your face, isnt entirely known
While insurance challenges exist, more policies are covering GLP-1 options like Wegovy or Zepbound thanks to their impressive outcomes
Strategic Implications The convergence of patent activity and scientific publication patterns points toward several strategic conclusions for organizations operating in this space
